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INTRODUCTION 
Rare diseases (RDs), including those of genetic origin, 
are defined by the European Union as life-threatening 
or chronically debilitating conditions whose prevalence 
is so low (less than 5 per 10 000) that special, combined 
efforts are needed to address them in order to prevent 
significant morbidity or perinatal or early mortality or a 
considerable reduction in an individual’s quality of life 
or socio-economic potential. This definition first ap-
peared in EU legislation in Regulation (EC) 141/2000 
of 16 December 1999, on orphan medicinal products 
and was extended to the public health field by Commis-
sion Communication on RDs: Europe’s challenges of 
11 November 2008, and by Council Recommendation 
on an action in the field of RDs, of 9 June 2009. Around 
6000 diseases are described in the Orphanet database 
(https://www.orpha.net), affecting between 6% and 8% 
of the European people. In other words, between 27 
and 36 million persons in the European Union are af-
fected, or will be affected in a moment of their life, by 
a rare disease. There is probably no other area of health 
care where collaboration between 28 different national 
approaches can be so efficient and effective. 
POLICIES AND ACTIONS
The Directive 2011/24/EU on the application of 
patients’ rights in cross-border healthcare clarifies pa-
tients’ rights to access safe and good quality treatment 
across EU. This Directive was the consequence of sev-
eral decisions of the European Court of Justice related 
to the free circulation of patients as part of the EU fun-
damental right of the free circulation of persons. The 
European Reference Networks (ERNs) are being set 
up under this 2011 Directive and the European Com-
mission adopted, through legal means the criteria and 
conditions which the European Reference Networks 
(ERNs) and the healthcare providers must fulfil. A new 
era for cooperation in the field of health was unveiled 
on 9 March 2017 as the first 24 ERNs were launched. 
Each of the 24 ERNs addresses groups of rare dis-
eases including bone disorders, endocrine conditions, 
hereditary metabolic disorders, connective tissue and 
musculoskeletal diseases, immunodeficiency, autoin-
flammatory and autoimmune diseases; oncological and 
non-oncological haematological diseases. These net-
works, each having a co-ordinator, involve more than 
900 highly-specialised healthcare units from over 300 
hospitals in 26 Member States. 
The overarching objective of ERNs is that patients 
have an improved access to quality diagnosis, care and 
treatment. This should be achieved by facilitating the 
mobility of the knowledge; only if absolutely necessary 
the mobility of patients should be envisaged (https://
ec.europa.eu/health/ern_en). Each ERN operates by 
sharing and generating data and knowledge, clinical 
guidelines and performing training and e-learning. The 
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Abstract 
Rare diseases (RDs) are defined by the European Union as life-threatening or chronical-
ly debilitating conditions, with a prevalence lower than 5 per 10 000 inhabitants. Around 
6000 diseases are described, affecting between 6% and 8% of the European population. 
Due to their severity, diffusion and multi-faceted aspects, RD are an area where collabo-
ration in public health, health care and research provides a major integrated added value. 
Main areas for policy actions include: the development and implementation of European 
Reference Networks, as a main strategy for sharing of knowledge, clinical expertise and 
foster research; integration of high-quality patient registries, biobanks, and bioinformat-
ics support, as key infrastructure tools addressing research and healthcare needs; the 
implementation of National Plans on RD in EU Member States by sharing experiences, 
capacity building and linking national efforts through a common strategy at a Euro-
pean level; actions driven by the recommendations for primary prevention of congenital 
anomalies (the main RD group with multifactorial aetiology); policy provisions to foster 
research and development of orphan drugs.
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ERN initiative is mainly driven by EU countries. The 
Board of Member States is the formal body in charge of 
the approval and termination of networks and member-
ships as provided in the Commission’s Implementing 
Decision [1]. The Board is comprised of representatives 
of the 28 EU countries and the EEA countries.
In this context, the 4th  Conference on European 
Reference Networks, “ERNs in action” [2] organized 
by the European Commission took place on 21 and 22 
November 2018 in Brussels with the involvement of the 
main ERNs stakeholders, including ERNs represen-
tatives, policy makers, national authorities, scientific 
communities and  patients associations. ERNs are an 
excellent example of pan-European collaboration, unit-
ing many different stakeholder groups (e.g. patients, 
Health Care Providers, scientists, policy makers). The 
ERNs have access to a dedicated Clinical Patient Man-
agement System (CPMS) [3] to provide virtual, cross-
expert and cross-border consultations for real patients 
whose cases warrant the pooling of knowledge across 
the ERN community. The ERNs main challenges for 
the future are linked to the long-term sustainability and 
their integration in healthcare systems of the Countries. 
The European Commission provides non-competi-
tive funding opportunities and the 2018 Public Health 
Programme dedicates € 13.8 million to “Multiannual 
specific grant agreements for European Reference 
Networks” for the subsequent 3 years. The Networks 
expect also to receive the outcomes of applications to 
a Call launched via the Connecting Europe Facility 
(CEF), to support the ERNs in engaging with and us-
ing the CPMS.
Cooperation at EU level makes a real difference to 
rare diseases patients and their families, as well as the 
health professionals helping them. No country alone 
has the knowledge and capacity to treat all types of rare, 
complex and low-prevalence conditions and diseases, 
but by cooperating and exchanging life-saving knowl-
edge at European level through ERNs, patients across 
the EU will have access to the best expertise available.
One of the main obstacles to clinical research and 
treatment advancements in RDs is the difficulty in con-
ducting clinical trials. Clinical trials in RDs have to deal 
with the geographic spread of patients but also with the 
high heterogeneity within the same disease. The ap-
proval process of orphan drugs by regulatory agencies 
may also have to deal with limitations inherent to the 
small populations. 
RD patient registries are powerful instruments that 
help and facilitate clinical research, planning of clinical 
trials, patient care as well as healthcare management. A 
pivotal aspect is the connection of registries with bio-
banks and clinical bioinformatics for RD research, as 
developed by the European project RD-Connect [4]. 
In particular, registries constitute a key support to ERN 
activities. A rapid proliferation of RD registries has oc-
curred during the last years, either disease-specific or 
targeting RD groups at national [5], European [6] or 
international level. The analysis performed within the 
EPIRARE project (www.epirare.eu) identified three 
main typologies of registries, on the basis of their main 
purpose: public health, clinical and genetic research, 
and treatment registries [7]. Registries should maintain 
high-quality standards. Recommendations for quality 
implementation deal with such aspects as governance, 
Findable, Accessible, Interoperable and Reusable 
(FAIR) data, documentation, training, and auditing [8].
On these bases, the European Commission has pro-
posed a common platform of RDs registries that will 
allow improving and increasing integrated uses. The 
European Commission Joint Research Centre (JRC) 
develops and maintains this European Platform on 
Rare Diseases Registration. Currently, the migration of 
two surveillance networks, the European Surveillance 
of Congenital Anomalies (EUROCAT) (www.eurocat-
network.eu) and the Surveillance of Cerebral Palsy in 
Europe (SCPE) (www.scpenetwork.eu), has been fully 
achieved. 
One main function of the EU RD Platform is to en-
able interoperability for the 747 existing RD registries 
in Europe according to the Orphanet inventory [9]. 
The second function is to offer a sustainable solution 
for two large European surveillance networks: Europe-
an Surveillance of Congenital Anomalies (EUROCAT) 
and Surveillance of Cerebral Palsy in Europe (SCPE). 
EUROCAT is European network of population-based 
registries for the epidemiological surveillance of con-
genital anomalies. It covers about one third of the Euro-
pean birth population. The Central Database contains 
about 800 000 cases with congenital anomalies among 
livebirths, stillbirths and terminations of pregnancy, re-
ported using the same standardised classification and 
coding. These high quality data enables epidemiologi-
cal surveillance of congenital anomalies, which includes 
estimating prevalence, prenatal diagnosis and perinatal 
mortality rates and the detection of teratogenic expo-
sures among others.
Due to the rarity of the diseases, none of the 28 EU 
Member States have enough data to conduct epidemio-
logical, clinical or pharmacological studies to advance 
knowledge in this field. The information that is avail-
able is fragmented in these hundreds of registries across 
Europe, and until now there have been no uniform, ac-
cepted standards to govern the collection and organ-
isation of these data. Capitalizing on the earlier set of 
indicators and common data elements proosed by the 
project EPIRARE [10], the “Set of Common Data Ele-
ments for Rare Diseases Registration” [11] is the first 
practical instrument released by the EU RD Platform 
aiming for an increased interoperability of the data reg-
istries. It defines the minimum data elements to be reg-
istered by all rare diseases registries across Europe, and 
provides instructions on how and in which format each 
data element should be registered. 
The document describes the 16 data elements con-
sidered to be essential to enable further research. They 
refer to patient’s personal data, diagnosis, disease his-
tory and care pathway, as well as information to be pro-
vided for research purposes. All existing and new data 
registries across Europe are recommended to use this 
standard as the basis for their data collection activities. 
The standard was produced by a Working Group coor-
dinated by the JRC and composed of experts from EU 
projects working on common data sets: EUCERD Joint 
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Action, EPIRARE and RD-Connect.
European Commission JRC is planning to use the 
European Rare Disease Registry Infrastructure (ER-
DRI) in order to fine tune the tools even further to per-
fectly fit all stakeholder’s needs. ERDRI is part of the 
European Platform on Rare Diseases Registration (EU 
RD Platform). By promoting interoperability between 
data sources, the EU RD Platform supports knowledge 
generation on rare diseases and helps reaching the nec-
essary critical numbers to conduct epidemiological, 
clinical, translational, pharmacological and other stud-
ies and research for advancing diagnosis and treatment 
for RD patients. The semantic interoperability is based 
on the collection of metadata on all data elements col-
lected by participating registries. Additionally, Europe-
an Directory of RD registries will be created containing 
the list of participating RD registries, descriptive infor-
mation, specific rare disease addressed, scope, operat-
ing institution, etc. 
A list of the data elements collected by the registries 
according to these MDR (Central Metadata Reposi-
tory) will be the core components of the European RD 
Registry Data Warehouse constituted by aggregated 
data and a Reporting data set (RDS) with a Subset of 
Common Data Set without patient identification. That 
will create added value for all stakeholders and a se-
lected European RD data publicly access. The general 
benefits of EDRI ant the created interoperability could 
be the maximisation of the utility of participating regis-
tries, enabling use of data across the registries, to pro-
vide accelerated communication, enabling automated 
data (searching/finding), enabling studies and research, 
extended use and re-use of existing data for various pur-
poses.
A very useful and promising tool to reinforce and com-
plement the European Platform on Rare Diseases Reg-
istration is the European Union Project RD-Connect 
(https://rd-connect.eu/). Patient registries, biobanks, 
and bioinformatics support are key infrastructure tools 
required for genomic research in rare disease; data shar-
ing and linking of patients, samples, and analysis is also 
essential. The infrastructure developed by RD-Connect 
supports research in rare disease to find new genes, bio-
markers, and therapeutic targets more quickly and ef-
ficiently. Its ultimate goal will be to improve outcomes 
for rare disease patients via major improvements in 
diagnostics and therapeutics. The therapeutics market 
in rare disease has strong growth potential due to the 
high (and unmet) medical needs for most rare diseases. 
Genomic research and development will thus be highly 
relevant for many markets, including genetic testing, 
biomarkers, and therapeutics [12].
The Council Recommendation of June 2009 recom-
mended that Member States adopt, by the end of 2013, 
a national plan or strategy for rare diseases [13]. 25 
countries have adopted a national plan or strategy for 
rare diseases (NP/NS) compared to only 4 in 2008, and 
the focus has moved more from “adopting” to actually 
implementing and evaluating the success of these first 
(and sometimes second) national plans or strategies. In 
the critical preparatory phase, the EUROPLAN project 
[14] has been pivotal in order to share relevant experi-
ences within countries, promote capacity building and 
link national efforts through a common strategy at a 
European level. Therefore, EUROPLAN facilitated the 
implementation of National Plans in almost all EU and 
several non-EU Countries [15]. 
At Member State level, there is a great heterogeneity 
in the state of advancement of national policies, plans 
or strategies for rare diseases. Significant progress has 
been made towards this goal: 13 countries have time 
bound NP/NS which were still apparently active in 
July 2018: Austria, Croatia, Czech Republic, Estonia, 
France, Hungary, Ireland, Luxembourg, Netherlands, 
Portugal, Romania, Slovak Republic and Slovenia. 6 
countries adopted time-bound NP/NS which had ex-
pired by July of 2018 and appear to have been replaced/
renewed: Bulgaria, Finland, Greece, Italy, Latvia and 
Lithuania. The following countries adopted NP/NS 
which appear to be “ongoing” (i.e. according to the data 
received, do not cover specific time periods): Belgium, 
Cyprus, Denmark, Germany, Spain, United Kingdom. 
Three EU MS appear not to have adopted a NP/NS: 
Poland, Malta and Sweden. Switzerland and Norway 
also now have a RD plan or strategy [16].
It is interesting to mention that in other zones of the 
World a lot of countries have adopted NP/NS following 
the European model. This is the case in: Brazil, Colom-
bia, Peru, Argentina, Japan, Singapore, Taiwan, South 
Korea, India (on discussion), Russia, Ukraine, Kazakh-
stan and others.
Another very relevant EU action, impossible to im-
plement from a single Member State, is the revision of 
the International Classification of Diseases (ICD). The 
EU is cooperating closely with the World Health Orga-
nization (WHO) in revising the existing International 
Classification of Diseases (ICD) to ensure better codi-
fication and classification of RDs in the ICD 11th ver-
sion [17], which should be adequately coded and trace-
able in all health information systems contributing to 
their adequate recognition in national health care and 
reimbursement systems. 
Until recently there was no systematic effort to es-
tablish an inventory of rare disorders, except in the field 
of genetic defects where the Online Mendelian Inheri-
tance in Man (OMIM) (www.omim.org) had started to 
document knowledge on genetic phenotypes as a proxy 
for genes, then on human genes when identified, as ear-
ly as 1966 [18]. The compilation of an inventory of rare 
diseases, beyond genetic diseases, started in a system-
atic way in 1996, in the context of the rare disease data-
base and knowledge base, Orphanet, established jointly 
by the French National Institute of Health and Medi-
cal Research (INSERM) and the French Ministry of 
Health [19] before being supported by the EUCERD 
Joint Action between the Member States of the Euro-
pean Union [20]. As a pilot initiative Orphanet not only 
collected information on rare diseases published in the 
scientific literature, but also classified them, from 2007 
onwards, with a poly-hierarchy approach, each clini-
cal entity being assigned an Orpha number. This effort 
was supported by the European Commission which not 
only co-financed Orphanet from 2001 onwards still to-
day, but also established, in January 2004, a Rare Dis-
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eases Task Force with the mandate to contribute im-
prove the codification of rare diseases, amongst other 
public health objectives [21].
In November 2014 a Recommendation on Ways to 
Improve Codification for Rare Disease in Health In-
formation Systems [22] was adopted by the EU Com-
mission Expert Group on Rare Diseases. The document 
includes a recommendation to further promote Orpha 
codes within the development of ICD11 in order to al-
low a seamless transition of rare disease classification 
from Orpha codes to ICD11 when the latter is released. 
The Expert Group recommends that Member States 
implement the Orpha codes system and that codifica-
tion of rare diseases be addressed within Member State 
rare disease national plans.
An assessment of the number of rare clinical entities 
having a specific code in ICD 10 can be derived from 
the effort carried out by Orphanet to cross-reference 
Orpha codes with ICD 10 codes, starting from the Or-
phanet list of rare clinical entities defined as a clinically 
unique, distinct entity, whatever the number and nature 
of the causes, and following the European definition 
for rarity, i.e. a prevalence equal of no more than 1 in 
2000 in the general population of Europe (Figure 1). 
The cross-referencing is based on the 2010 online ver-
sion of the ICD-10, but takes into account the official 
WHO updates endorsed in 2011 and 2012. In Janu-
ary 2015, among the over 6954 clinical entities listed 
by Orphanet, 355 of them only have a unique specific 
code in ICD 10. Each entry in the health information 
systems (group, disorder, subtype) is given a unique and 
stable ORPHA number (the Orpha codes). Each en-
try is given a preferred term and as many synonyms as 
necessary. In fact the situation is complex as one ICD 
code sometimes corresponds to one Orpha code, but 
also one ICD code can correspond to a group of rare 
entities or to a group of both rare and non-rare entities. 
To increase rare disease representation in ICD-11, the 
objective is to expand the number of specific codes.
The Systematized Nomenclature of Medicine Clini-
cal Terms (SNOMED CT) (www.snomed.org) is run by 
the International Health Terminology Standards Devel-
opment Organisation and is available in over 50 coun-
tries. It has been adopted as the standard terminology 
for the National Health Service in the UK and includes 
not only disease classification but also other medical 
terminology areas. Nearly 3000 rare diseases have a 
specific SNOMED CT code. The lack of data about 
rare diseases, due to the absence of codes for most rare 
diseases, deserves a special effort in epidemiology to 
make rare diseases more visible in the healthcare sys-
tems, in parallel with the ongoing process to incorpo-
rate codes for rare diseases in ICD and SNOMED-CT, 
as this process will not provide full results before several 
years [22]. 
The implementation of ORPHA codes [23] in nation-
al health information systems is ongoing. In addition to 
the progression of this implementation in Germany and 
France, pilot experiences are being conducted in Hun-
gary, Latvia and Norway. ORPHA codes are currently 
being used in centres of expertise in the Netherlands 
and Slovenia. ORPHA codes are also being implement-
ed in patient registries in Portugal, UK and Spain. In 
Switzerland, the Hôpitaux Universitaires de Genève 
and CHUV implement ORPHA codes in digital pa-
tient records since 2015. The use of ORPHA codes as a 
complement to already existing coding systems is being 
explored in most EU Member States [24], as recom-
mended by the European Commission Expert Group 
on Rare Diseases. 
In the meantime, the European Commission sup-
ports the Orphanet approach to improve quality and 
traceability of RDs in health information systems by 
using “Orphacodes” on a voluntary basis at a national 
ICD9 + ICD10 + OMIM
ICD9 + ICD10 + Other
ICD10 + OMIM
ICD10 + OMIM
ICD10 + OMIM + SNOMED-CT + Other
ICD10 + SNOMED-CT
OMIM
ORPHA
Coding systems for coding Rare Disease
patients in Europe (as of May 2017)
According to the RD-ACTION survey answers
Figure 1
Overview of Rare Diseases coding terminologies in Europe.
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level. These Orphacodes refers to the Orphanet classifi-
cation of diseases and it is a stable and evidence-based 
nomenclature based on published expert classifications.
The European Joint Programme – Rare Diseases 
(EJP-RD) [25] is an instrument from the European 
Commission allowing high-level strategic organization 
and performance of research activities in an organized 
and transversal manner. It is operated by Programme 
Owners (typically ministries) and Programme Manag-
ers (Research Funding and Research Performing or-
ganizations) in conjunction with other relevant stake-
holders (e.g. patients’ organisations, regulatory bodies 
and the private sector). The 2018 Work Programme 
of the EU Horizon 2020 Programme included a very 
important call, to establish an EJP in the field of rare 
disease research with an EC budget of € 55 million for 
5 years (2019-2023). In preparation for this call, an ex-
pert drafting committee was assembled in late 2016, 
to outline the contents of an EJP for RD. The basic 
goal was to support translational research in the rare 
disease arena, from bench to bedside and back again: in 
other words, to develop a sustainable ecosystem allow-
ing a virtuous circle between rare disease care, research 
and medical innovation. The proposal was further de-
veloped during the course of 2017 and 2018, and the 
drafting group expanded to a vast consortium of 85 
partners, led by the French INSERM. The proposal was 
submitted in April 2018 and approved in July, with an 
anticipated start date of January 2019. The total bud-
get of the entire EJP is expected to exceed € 110 mil-
lion (€ 55 million directly from the EC, supplemented 
with substantial national and in-kind contributions). 33 
countries will participate in total, from 25 EU Members 
States, 8 Associated Countries, and one Third Country 
(Canada). The main goals of the EJP RD are: to im-
prove the integration, the efficacy, the production and 
the social impact of research on RD through the de-
velopment, demonstration and promotion of Europe/ 
worldwide sharing of research and clinical data, materi-
als, processes, knowledge and know-how; to implement 
and further develop an efficient model of financial 
support for all types of research on RD (fundamental, 
clinical, epidemiological, social, economic, health ser-
vice) coupled with accelerated exploitation of research 
results for benefit of patients. EJP-RD is an inclusive 
effort, building on existing resources, experiences and 
networks including eRare, Orphanet, RD-Connect, 
EURORDIS, ERNs, and research infrastructures like 
ELIXIR (www.elixir-europe.org), BBMRI (www.bbmri-
eric.eu), EATRIS (https://eatris.eu/), ECRIN (www.
ecrin.org), INFRAFRONTIER (www.infrafrontier.eu), 
amongst many others.
Primary prevention and health promotion are also 
relevant to RD policies. At least 20% of RD have a 
multifactorial basis. In particular, congenital anomalies 
(CA) are the paradigm example of RD liable to primary 
prevention actions, since most of them have a multi-
factorial (gene-environment) etiology. However, the in-
sufficient attention to an integrated preventive strategy 
has led to the prevalence of CA remaining relatively 
stable in recent decades. On 2012 two European proj-
ects, EUROCAT and EUROPLAN, have joined efforts 
to provide the first science-based and comprehensive 
set of recommendations for the primary prevention of 
CA in the European Union. The resulting EUROCAT-
EUROPLAN “Recommendations on Policies to Be 
Considered for the Primary Prevention of Congenital 
Anomalies in National Plans and Strategies on Rare 
Diseases” [26] were endorsed by European Union in 
2013. The recommendations exploit interdisciplinary 
expertise encompassing drugs, diet, lifestyles, maternal 
health status, and the environment; evidence-based ac-
tions are pointed out aimed at reducing risk factors and 
at increasing protective factors and behaviors at both 
individual and population level. The recommendations 
therefore provide a comprehensive tool to implement 
primary prevention into national policies on RD in Eu-
rope and elsewhere [27, 28]. 
Recognising that the rare diseases constitutes a world 
problem for which the transatlantic cooperation was 
an obvious necessity the International Rare Diseases 
Research Consortium (IRDiRC) (www.irdirc.org) was 
created in 2014 as a platform for cooperation between 
the European Union, USA and Canada. IRDiRC an-
nounced a new vision and goals for 2017-2027. IRDiRC 
was conceived with two main goals: to contribute to the 
development of 200 new therapies and the means to 
diagnose most rare diseases by the year 2020. The goal 
to deliver 200 new therapies was achieved in early 2017, 
while the goal for diagnostics is considered to be reach-
able as well. IRDiRC goals are to ‘enable all people liv-
ing with a rare disease to receive an accurate diagnosis, 
care, and available therapy within one year of coming to 
medical attention’. The last six years have seen consid-
erable progress on these goals: the goal to deliver 200 
new therapies was achieved in early 2017 – three years 
earlier than expected – and the goal for diagnostics is 
within reach. These accomplishments were celebrated 
at the 3rd IRDiRC Conference in Paris in February 
2017 [29].
From the IRDiRC perspective, an accurate molecular 
diagnosis [30] is essential for informed patient manage-
ment and family counselling, as well as for rare disease 
research including natural history studies, biomarker 
identification and clinical trials. There are ~7000 rare 
diseases and the relevant gene is known (as of 2016) 
for approximately half of these, thus around 3500 are 
still without a defined molecular pathogenesis. In ad-
dition, a significant fraction of rare disease patients are 
without a molecular diagnosis due to a lack of universal 
accessibility of diagnostic testing. For diagnostic testing 
to be available for the majority of rare diseases by the 
year 2020, IRDiRC must focus on the discovery of the 
genes for the 3500 phenotypes that are currently with-
out an associated disease gene [31]. Another challenge 
faced is diagnostics beyond the exome, and approaches 
to overcome these barriers to gene discovery are lim-
ited; the development of innovative approaches for dis-
covery is required to solve these unsolved conditions, 
and IRDiRC aims to gather key researchers and review 
strategies to address this challenge [32]. International 
efforts to establish guidelines for the clinical reporting 
of genomic sequencing in a clinical setting, including 
the approach to report incidental findings, will expedite 
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the delivery of high-throughput and cost-effective test-
ing to the rare diseases patient community as a whole, 
e.g., guidelines for diagnostic next-generation sequenc-
ing developed by EuroGentest and the European So-
ciety of Human Genetics [33]. In addition, the neces-
sary bi-directional flow between the clinic and research 
will be enabled by the IRDiRC Policies and Guidelines 
[34].
IRDiRC is focused on accelerating progress in the 
field of rare disease research through international 
cooperation and collaboration [30], with the ultimate 
goals of enabling the means to provide a diagnosis for 
all rare diseases patients, and to contribute to the devel-
opment of new therapies for rare diseases. In order to 
increase the joint impact of rare diseases investment by 
funding agencies, industry, researchers, regulators, and 
rare diseases patient advocates, harmonization of ef-
forts that address common roadblocks is needed. To as-
sist in this task, IRDiRC developed a set of Policies and 
Guidelines [35], which are the principles that IRDiRC 
members agree to adhere to, focused on data sharing 
and standards, ontologies, diagnostics, biomarkers, 
patient registries, biobanks, natural history, therapeu-
tics, models, publication and intellectual property, and 
communications about the Consortium. The IRDiRC 
Policies and Guidelines are the detailed and world-
wide agreements of major public and private funding 
organizations to govern rare disease research, with the 
Consortium representing over 2 billion US dollar of in-
vestments. While it is too early to fully gauge the depth 
and magnitude of impact on rare disease research and 
patient benefit, the IRDiRC Policies and Guidelines 
have already significantly contributed in improving 
transparency and collaboration in this field. IRDiRC is 
now making steps towards addressing gaps and barriers 
in rare disease research; Task Forces are established to 
specifically address some of these gaps through policy 
recommendations and/or technical solutions. Rare dis-
ease research has made considerable progress in the last 
decade, and the IRDiRC Policies and Guidelines will 
further push the discovery progress of rare disease diag-
nosis and treatment, thereby advancing this important 
field of research.
According to the European legislation, a medicinal 
product can qualify for orphan designation under cer-
tain conditions. Today there are 221 orphan designa-
tions from which 164 initial orphan marketing authori-
sations and 22 extension of indication granted to date 
[36]. The medicine is assessed by the Committee of 
Orphan Medicinal Products (COMP) in the EMA (Eu-
ropean Medicines Agency). The EMA will now publish 
an orphan maintenance assessment report for every 
orphan-designated medicine as part of a medicine’s Eu-
ropean Public Assessment Report  (EPAR) after the 
European Commission has adopted its marketing au-
thorisation decision.
The European medicines regulatory system is based 
on a network of around 50 regulatory authorities from 
the 31 EEA countries (28 EU Member States plus Ice-
land, Liechtenstein and Norway), the European Com-
mission and EMA. This network is what makes the EU 
regulatory system unique.
Results from a recent study [37] confirm that the 
number of medicines for rare diseases has increased 
since after 2010 and that the number of medicines in 
use and the resources spent vary widely among Euro-
pean countries. Despite these differences, some medi-
cines are available in all countries and are mostly indi-
cated for treating rare cancers and immune diseases. 
Similarly, the European Organisation for Rare Diseases 
(EURORDIS) study in 2010 showed that oncology 
medicines for rare diseases were the most widely avail-
able in nine European countries analysed [38]. Further-
more, our mean time to first continuous use seems to 
be comparable with the findings from the 2007 EU-
RORDIS study that included 17 European countries 
[39]. The study reports the mean European time to first 
use of orphan medicines as 341 days (0.93 y) after mar-
keting authorization. In the study, the average time to 
first continuous use assessed for orphan medicines was 
1.6 years, which seems longer, but it represents uninter-
rupted use and includes the times of slower European 
markets. The study demonstrated that times to first 
use for orphan and non-orphan medicines did not dif-
fer in the biggest markets, whereas some smaller mar-
kets needed more time to introduce orphan medicines 
compared with non-orphan medicines, which could be 
due to higher prices. In Europe, half of the medicines 
for rare diseases introduced (orphan or not) are in use 
within 1 year after marketing authorization. The most 
successful countries in providing numerous medicines 
to the market in the quickest time are Germany, Nor-
way, Finland, Sweden, and France, as observed previ-
ously. These countries also have specific mechanisms to 
improve patient access to these medicines and to grant 
full or substantial reimbursement from public resources. 
Italy and Spain have introduced several medicines for 
rare diseases, but it takes them longer than 1 year until 
the medicines are first used. In addition, Italy enables 
full reimbursement of orphan medicines, whereas Spain 
covers medicines with therapeutic advantage. Austria 
and The Netherlands also provide many medicines in a 
short time and substantially cover orphan drugs. Simi-
larly, Ireland is fast in enabling first use, but reimburse-
ment depends on community and national schemes 
that may not cover the medicine. Also, the number of 
medicines reported is quite low and does not represent 
total product availability.
Smaller markets, such as the Bulgarian, Croatian, 
Czech, Greek, Hungary, Polish, Romanian, Slovenian, 
and Slovakian markets, offer between one-third and 
one-half of the medicines analyzed, which is a signifi-
cant number of medicines for rare diseases. However, 
the time to first use is much longer and more variable 
in these markets than in the larger European markets. 
The fight against inequalities and inequities for the 
access to orphan drugs for all the patients of rare diseas-
es around the EU constitutes a very relevant objective 
for the coming years even if the prices of such medica-
ments are a serious handicap for a single approach in all 
the European Union. The growth of pharmaceutical ex-
penditures due to new high-cost innovative medicines, 
under the current institutional framework, creates fi-
nancial challenges to health systems. The recognition 
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that the current path of growth cannot be continued in-
definitely leads to the search of new ways to ensure that 
innovation “that matters” is produced, that patients 
have access to innovation and that health systems are 
financially sustainable. This context leads to the discus-
sion of innovative payment models for new medicines 
(including orphan medicinal products) that improves 
the way the three above-mentioned objectives are met. 
It is unlikely that a single payment model will be opti-
mal for all situations. Some broad principles should be 
observed when defining specific payment models for in-
novative medicines and deciding on rewarding R&D in 
pharmaceutical products [40].
In 2017, the PRIority MEdicines (PRIME) scheme 
was launched by the EMA (European Medicines 
Agency). This initiative was launched in March 2016 to 
provide early and enhanced support to medicines that 
can potentially address patients’ unmet medical needs, 
came into its second year of application. The EMA ad-
opted a total of 81 eligibility recommendations in 2017, 
20% more than in 2016. The success rate for acceptance 
into PRIME remained low, with only one out of five 
applications being successful, to ensure the Agency fo-
cuses on the most promising medicines.
A last example of European Union cooperation in 
fields having an influence in the rare diseases policy 
is the Health technology assessment (HTA). HTA is 
a research-based tool to support decision-making in 
healthcare. HTA assesses the added value of  new or 
existing health technologies – medicines, medical de-
vices and diagnostic tools, surgical procedures, as well 
as measures for disease prevention, diagnosis or treat-
ment – compared with other health technologies. The 
HTA process is performed by currently about 50 Eu-
ropean HTA agencies. Fragmented approaches from 
HTA agencies may have a negative impact on R&D 
investment in Europe. The Commission  adopted its 
legislative initiative on 31 January 2018 [41]. The pro-
posed regulation on HTA aims to strengthen EU-level 
cooperation among Member States for assessing health 
technologies. According to the Commission, it would 
not only make innovative health tools reach patients 
faster, but also boost innovation and improve competi-
tiveness of the European healthcare sector, which ac-
counts for 10% of the EU’s GDP. Building on existing 
EU cooperation on HTA, including the HTA Network 
and the EUnetHTA Joint Action (www.eunethta.eu), 
the proposal would provide the basis for a permanent, 
sustainable cooperation.
The proposal covers new medicines and certain 
new medical devices. It focuses the future coopera-
tion (the “joint work”) on assessing clinical aspects of 
HTA, namely: the description of the health problem 
addressed by the health technology and the current 
use of other health technologies addressing that health 
problem; the description and technical characterisation 
of the health technology; the relative clinical effective-
ness and the relative safety of the health technology. 
Member States would continue to be responsible for 
assessing non-clinical (e.g. economic, social, ethical, 
organisational) aspects of HTA, as well as for making 
decisions on pricing and reimbursement.
The proposal provides for joint work in four areas: i) 
joint clinical assessments focusing on the most innova-
tive health technologies with the most potential impact 
for patients; ii) joint scientific consultations, whereby 
health technology developers (i.e. the pharmaceuti-
cal industry and medical-device manufacturers) can 
seek advice from HTA authorities; iii) identification 
of emerging health technologies (“horizon scanning”), 
with a view to identifying promising health technologies 
at an early stage; and iv) continuing voluntary coopera-
tion on other aspects of HTA.
The cooperation would be Member State-driven, 
with the Commission hosting a secretariat to provide 
administrative, scientific and IT support. Participa-
tion in the joint clinical assessments and use of the 
joint clinical assessment reports at Member State-level 
would become mandatory after six years: following the 
regulation’s entry into force, the Commission proposes 
a three-year period for adopting tertiary legislation, and 
another three-year (transitional) period to allow Mem-
ber States to fully adapt to the new system. Parliament’s 
Committee on the Environment, Public Health and 
Food Safety adopted the rapporteur’s draft report on 13 
September 2018. The committee report was endorsed 
in plenary on 3 October 2018 with 200 amendments to 
the Commission proposal.
All these European achievements after years of ac-
tion, are envisaged to be instrumental in guiding policy 
and research in the field of rare diseases in the forth-
coming years looking for a fruitful and beneficial future 
for rare disease patients and stakeholders.
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